Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Ophthalmology Innovation Source (OIS)

Ophthalmology Innovation Source (OIS)
Web Address: www.OIS.net

The Ophthalmology Innovation Summit (OIS) launched in 2009 as the first event to showcase novel therapies in development for unmet needs in ophthalmic disease and vision disorders.

Since then, the mission of uniting entrepreneurs, ophthalmic start-up companies, clinical thought leaders, industry executives and investment professionals to facilitate a powerful exchange of information and connections to drive innovation has evolved. Over the course of the following decade, OIS successfully expanded with additional high-caliber summits focused on the anterior segment, retina and optometry.

In 2020, OIS evolved into the Ophthalmology Innovation Source to expand our services beyond live events by delivering timely information and key insights through news, podcasts, videos and virtual programs. PLUS the newest and most exciting addition of the EyeDeal Sourceâ„¢ database of ophthalmic start-up companies and investors.

We welcome you to join the OIS community and improve vision on a global scale.

Further Resources

Close Popup